Dosing of BRAK and MEK inhibitors in melanoma

no point in taking a break

Jenny H. Lee, Matteo S. Carlino, Helen Rizos*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAFV600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAFV600-mutant melanoma patients.

Original languageEnglish
Pages (from-to)779-781
Number of pages3
JournalCancer Cell
Volume38
Issue number6
DOIs
Publication statusPublished - 14 Dec 2020

Fingerprint Dive into the research topics of 'Dosing of BRAK and MEK inhibitors in melanoma: no point in taking a break'. Together they form a unique fingerprint.

Cite this